What is Atrium Therapeutics, Inc.'s (RNA) StockRank?

MoatMap's StockRank for Atrium Therapeutics, Inc. (RNA) is 17/100, with a Strong Sell signal. This is a composite score combining Quality (37), Value (42), and Momentum (26) factor ranks across MoatMap's 19,000+ stock universe.

Does Atrium Therapeutics, Inc. have an economic moat?

Atrium Therapeutics, Inc. (RNA) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Atrium Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Atrium Therapeutics, Inc. (RNA) is Strong Sell, based on a StockRank of 17/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Atrium Therapeutics, Inc. in?

Atrium Therapeutics, Inc. (RNA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

RNA

STRONG SELLREMOVE

Atrium Therapeutics, Inc. · Healthcare · United States · $229M · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

—

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Atrium Therapeutics is a micro-cap healthcare entity with highly speculative prospects. It lacks the proven commercial products, high ROIC, and deep competitive moats required to satisfy our quality compounder criteria.

COMPANY DESCRIPTION

Atrium Therapeutics, Inc. is a biotechnology company dedicated to developing novel RNA-targeted therapeutics for rare and severe diseases. The company leverages its proprietary RNA delivery platform to target previously undruggable genetic pathways, establishing a strong intellectual property moat. It operates as an innovative clinical-stage player in the high-growth genetic medicine sector.

FINANCIAL SUMMARY

Year	2023	2024	2025	CAGR
Revenue	10M	11M	19M	38.1%
EPS	-0.37	-1.47	-2.89	—
Shares	17M	17M	17M	0.0%
Debt	10M	7M	4M	-38.9%
Equity	-71M	-61M	207M	—
Op CF	56M	-23M	-41M	—
Inv CF	-320,000	-266,000	-1M	—
Fin CF	-56M	23M	43M	—

PRICE (1M)-7.9%

SMA 50SMA 200

$12.37

RSI (14)

40.1

SCORE BREAKDOWN

Quality

ROIC

-32.5%21.0

ROE

—N/A

GP/Assets

-4.3%7.9

Op. Margin

-88.0%17.6

FCF/Assets

—N/A

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.01x87.3

Current Ratio

13.04x91.0

Value

P/E (TTM)

—N/A

EV/EBITDA

0.9x61.5

P/FCF

—N/A

P/B

0.9x81.3

P/S

5.8x37.0

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

—N/A

SMA 50/200

—N/A

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+20%33.6

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$229M

P/E (Forward)

-3.1x

Gross Margin

-32.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RNA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
RNA	Atrium Therapeutics, Inc.(you)	$229M	17	STRONG SELL
VYGR	Voyager Therapeutics, Inc.	$236M	17	STRONG SELL
CHRS	Coherus Oncology, Inc.	$255M	17	STRONG SELL
FHTX	Foghorn Therapeutics Inc.	$251M	16	STRONG SELL
CNTX	Context Therapeutics Inc.	$260M	16	STRONG SELL
KROS	Keros Therapeutics, Inc.	$225M	14	STRONG SELL
CAMP	CAMP4 THERAPEUTICS CORPORATION	$233M	13	STRONG SELL
ARCT	Arcturus Therapeutics Holdings Inc.	$225M	22	SELL
OBIO	Orchestra BioMed Holdings, Inc.	$238M	22	SELL
TRDA	Entrada Therapeutics, Inc.	$265M	13	STRONG SELL

Peer medians: ROE -22.4% · P/E 25.1x · Gross margin 44.3%

Atrium Therapeutics, Inc. (RNA) — Stock Score Summary

Atrium Therapeutics, Inc. (RNA) has a MoatMap StockRank of 17/100 based on Quality (37/100), Value (42/100), and Momentum (26/100) factor scores. The current signal is STRONG SELL. Atrium Therapeutics is a micro-cap healthcare entity with highly speculative prospects. It lacks the proven commercial products, high ROIC, and deep competitive moats required to satisfy our quality compounder criteria.

Key Financial Metrics

Price	$12.37
Market Cap	$229M
P/E (Forward)	-3.07
Price/Book	0.90
Return on Invested Capital	-32.5%
Debt/Equity	1.15
Gross Margin	-32.9%
Operating Margin	-88.0%
Revenue Growth	1148.3%

Atrium Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Atrium Therapeutics, Inc.’s (RNA) StockRank?: MoatMap’s StockRank for Atrium Therapeutics, Inc. (RNA) is 17/100, with a Strong Sell signal. It is a composite of Quality (37), Value (42), and Momentum (26) factor ranks across MoatMap’s 19,000+ stock universe.
Does Atrium Therapeutics, Inc. have an economic moat?: Atrium Therapeutics, Inc. (RNA) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Atrium Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Atrium Therapeutics, Inc. (RNA) is Strong Sell, based on a StockRank of 17/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Atrium Therapeutics, Inc. in?: Atrium Therapeutics, Inc. (RNA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).